- Canada
- /
- Medical Equipment
- /
- TSXV:MIR
MedMira Second Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)
MedMira (CVE:MIR) Second Quarter 2024 Results
Key Financial Results
- Revenue: CA$148.7k (down 13% from 2Q 2023).
- Net loss: CA$590.8k (loss widened by 20% from 2Q 2023).
- CA$0.001 loss per share (in line with 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MedMira shares are up 13% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 5 warning signs for MedMira (4 are significant!) that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:MIR
MedMira
A biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally.
Medium-low with worrying balance sheet.
